TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01874665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Ponatinib 45 mg, tablets, orally, once-daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Ponatinib 45 mg, tablets, orally, once-daily.
Study: NCT04693845

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Assessment and Management of Suicidality
Description: CAMS is a suicide-focused intervention that stabilizes the suicidal patient and identifies, targets, and treats patient-defined suicidal drivers-the problems (e.g., trauma, financial issues, relationship loss) that compel a patient to consider suicide. CAMS is theoretically agnostic, patient-centered, and can be used across different suicidal populations and clinical settings.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment as Usual was based on the staff, policies, and procedures of the community mental health center Next Day Appointment clinic (CMHC) affiliated with our university. Research therapists and the research psychiatrist were hired from the CMHC staff who followed standard CMHC policies and procedures.
Study: NCT01860807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibudilast
Study: NCT01860807

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00003178

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cladribine
Study: NCT00823446

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revera Wound Care
Description: Revalesio Part Number MDW0060

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Sodium Chloride for Irrigation
Study: NCT03146897

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supplementary Food
Description: Supplementary food for treating MAM

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supplementary Food
Description: Supplementary food for treating MAM

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supplementary Food
Description: Supplementary food for treating MAM

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supplementary Food
Description: Supplementary food for treating MAM
Study: NCT03019198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid Injectable Solution
Description: Intravenous 15 mg per kilogram tranexamic acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Concentrate
Study: NCT02716077

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FDG PET/CT imaging
Study: NCT02794714

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deep neuromuscular blockade
Description: Deep neuromuscular blockade attained during surgery using Rocuronium 0.6mg/kg at induction of anesthesia with intermittent boluses of 0.15 - 0.2 mg/kg to maintain a Post Tetanic Count (PTC) of 1-2 throughout surgery. Neuromuscular blockade reversed at the end of surgery with Sugammadex 4mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moderate neuromuscular blockade
Description: Moderate neuromuscular blockade attained during surgery using Rocuronium 0.6mg/kg at induction with intermittent boluses of 0.15 - 0.2 mg/kg to maintain Train of Four Count (TOFC) of 2 throughout surgery. Neuromuscular blockade reversed at the end of surgery with Sugammadex 2mg/kg.
Study: NCT03463434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air Fluidized Therapy
Description: AFT bed used for pressure injury treatment
Study: NCT00003178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cladribine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cladribine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Study: NCT03218605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical activity
Description: Subjects performed five activities: running, static stretch, dynamic stretch, cycling and rope skipping
Study: NCT00649233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg
Description: 100/50mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopressor HCT® Tablets 100/50 mg
Description: 100/50mg, single dose fed
Study: NCT03279354

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Move app intervention
Description: All the recruited parent-child pairs will be randomized after baseline assessment by an independent statistician using computer randomization tool to either the FAMILY MOVE app intervention group or the HK FitNuts app control group with a 1:1 allocation ratio. Although both groups receive a stand-alone app, the apps have distinct design features: use of competition and point elements (FAMILY MOVE app) or use of traditional demonstration elements (HK FitNuts app). After both groups have completed the 8-week intervention study and follow up measurements at 1 month, 6 months and 12 months after intervention, the control group will receive the same FAMILY MOVE app. Outcome assessments will be conducted by a trained interviewer blinded to the subject group allocation.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: HK FitNuts app intervention
Description: The parent-child pairs in the control group will be given a link to download the HK FitNuts app which was developed by Hong Kong Association of Sports Medicine and Sports Science, Department of Orthopaedics \& Traumatology of the Chinese University of Hong Kong and Hong Kong Dietitians Association to promote healthy lifestyle in Hong Kong. The app includes short video clips demonstrating basic individual exercise moves and provides other textual information related to PA. However, it does not have push notification function. In order to ensure that the intervention and control group will receive equal attention from our research team, we shall send a text about HK FitNuts and general exercise information to participants in the control group three times per week. Same as participants in the intervention group, the control group will also be asked to provide their weekly app usage and PA pattern by completing an online log at the end of each intervention week.
Study: NCT03924505

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Organize and Mobilize for Implementation Effectiveness
Description: Our trial is trying to understand how a multi-faceted, facilitation-based implementation strategy advances effective implementation of naloxone within syringe services programs

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dissemination
Description: Our comparison group receives dissemination of best practice recommendations for naloxone implementation.
Study: NCT04633603

Intervention type: DEVICE
Intervention: FeverFriend mobile application
Description: Registration, documentation of patients profile, documentation of fever events, following advice regarding the patient and the care-giver, documentation of follow up notifications.
Study: NCT02211092

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Description: A 12 week individually tailored home-based physical activity program with goal-setting, a physical activity self-monitoring technique, and weekly telephone calls provided by the intervener for coaching and support.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Access to usual community resources but no active lifestyle coaching.
Study: NCT01399970

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Teleconsultation Arm (MTA)
Description: In addition to a face-to-face visit at baseline, patients will conduct mobile visits at home every two weeks. The general practitioner of choice will perform examinations, such as laboratory or occasionally pregnancy tests every 4 weeks according to the treatment guidelines.

Intervention type: OTHER
Group type: OTHER
Intervention: Outpatient Consultation Arm (OCA)
Description: Patients will receive routine outpatient care at the clinic according to the treatment guidelines, and will be scheduled for outpatient visits every 4 weeks.
Study: NCT03807401

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prismatic goggles
Description: Goggles inducing a lateral displacement of the virtual field of ten degrees. Participants will be asked to wear those goggles during adaptation session and to perform pointing movement toward visual target.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality device
Description: The lateral displacement will be simulated thanks to a virtual reality environment. Participants will wear an Oculus Rift instead of the prismatic goggles and will perform pointing movement as well.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prismatic goggles
Description: Goggles inducing a lateral displacement of the virtual field of ten degrees. Participants will be asked to wear those goggles during adaptation session and to mentally perform pointing movement toward visual target. There will be no concurrent movement execution.
Study: NCT04296851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide
Description: The subjects will be randomly assigned in a 2:1 ratio to receive niclosamide or identical-appearing placebo tablets orally for 6 months: niclosamide 650mg once a day in arm 1, placebo once a day in arm 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The subjects will be randomly assigned in a 2:1 ratio to receive niclosamide or identical-appearing placebo tablets orally for 6 months: niclosamide 650mg once a day in arm 1, placebo once a day in arm 2.
Study: NCT01967095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Cycle 1, week 1 (D1-D7) will consist of pulse dose erlotinib on D1 \& D2 without daily low dose erlotinib on D3-7. For all subsequent weeks, patients will take high dose erlotinib on D1 \& D2, \& will receive erlotinib 50 mg oral daily x 5 days on days 3-7. On days 1 \& 2, patients will take one of the following doses of erlotinib, depending on the dose cohort they are enrolled in: Dose level 1 600 mg oral daily on D1, D2 Dose level 2 750 mg oral daily on D1, D2 Dose level 3 900 mg oral daily on D1, D2 Dose level 4 1050 mg oral daily on D1, D2. An additional Dose -1 (pulse dose erlotinib on D1, D2 with 25 mg oral daily x 5 days in D3-D7) will be reserved, in the unlikely situation that Dose 1 is proved too toxic. If Dose -1 is tolerated well (600mg oral daily D1, D2 \& 25mg oral daily D3-D7), pulse dose escalation can continue as described above, with erlotinib at the daily low dose of 25 mg oral on D3-D7.
Study: NCT04074382

Intervention type: OTHER
Intervention: Online Questionnaires
Description: We will use online questionnaires to complete research into functional outcomes after trauma

Intervention type: OTHER
Intervention: Online Questionnaires
Description: We will use online questionnaires to complete research into functional outcomes after trauma

Intervention type: OTHER
Intervention: Qualitative Interviews
Description: We will undertake qualitative interviews (remote or face to face) to shed more light on reasons for functional outcomes after trauma

Intervention type: OTHER
Intervention: Qualitative Interviews
Description: We will undertake qualitative interviews (remote or face to face) to shed more light on reasons for functional outcomes after trauma
Study: NCT04202315

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Utilizing Virtual Reality during external fixator removal in outpatient clinic setting.
Study: NCT03453996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Computerized clinical decision support intervention. This intervention consists of 2 decision support components for CI-AKI prevention:~1. Estimation of safe contrast limit to reduce the relative risk of CI-AKI by 20% (ePRISM Acute Kidney Injury Model with Contrast Sensitivities and Dialysis Risk software from Health Outcomes Sciences)~2. Patient weight and left ventricular end diastolic pressure (LVEDP) based intravenous crystalloid fluid recommendation.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Usual procedural care provided by cardiologist without introduction of the computerized clinical decision support information.
Study: NCT01078298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: varenicline tablets titrated to 1 mg BID during 1st week and then 1 mg BID for 11 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablets matched in appearance and dosage to varenicline tablets
Study: NCT01611428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipragliflozin
Description: Oral and Intravenous (i.v.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipragliflozin
Description: Oral and Intravenous (i.v.)
Study: NCT02376296

Intervention type: DRUG
Intervention: docetaxel
Description: 3-weekly docetaxel therapy (starting dose of 75 mg/m2)

Intervention type: DRUG
Intervention: docetaxel
Description: 3-weekly docetaxel therapy (starting dose of 75 mg/m2)

Intervention type: OTHER
Intervention: Blood draws
Description: Blood draws for determination of docetaxel plasma levels and exposure (AUC)

Intervention type: OTHER
Intervention: Blood draws
Description: Blood draws for determination of docetaxel plasma levels and exposure (AUC)
Study: NCT03318081

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive function rehabilitation and bias modification
Description: cognitive rehabilitation focus on the deficits executive funcitin and elevated cognitive bias

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive function rehabilitation and bias modification
Description: cognitive rehabilitation focus on the deficits executive funcitin and elevated cognitive bias
Study: NCT00655512

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pimecrolimus 1% cream
Description: twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pimecrolimus 1% cream
Description: twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pimecrolimus 1% cream
Description: twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocortisonacetat 1% cream
Description: twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocortisonacetat 1% cream
Description: twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocortisonacetat 1% cream
Description: twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: betamethasonvalerat 0,1% cream
Description: twice a day one fingertip at the testareas (forearm/back of the hand) for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: betamethasonvalerat 0,1% cream
Description: twice a day one fingertip at the testareas (forearm/back of the hand) for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: betamethasonvalerat 0,1% cream
Description: twice a day one fingertip at the testareas (forearm/back of the hand) for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clobetasol-17-propionat 0,05% cream
Description: twice a day one fingertip at the testareas (forearm/back of the hand) for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clobetasol-17-propionat 0,05% cream
Description: twice a day one fingertip at the testareas (forearm/back of the hand) for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clobetasol-17-propionat 0,05% cream
Description: twice a day one fingertip at the testareas (forearm/back of the hand) for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks
Study: NCT03218228

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: implants in periodontitis
Description: it targets immediate implant placement in patients suffering from aggressive periodontitis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implants in periodontitis
Description: it targets immediate implant placement in patients suffering from aggressive periodontitis
Study: NCT00939471

Intervention type: DEVICE
Group type: OTHER
Intervention: Relieva™ Balloon Sinuplasty™ System
Description: Balloon dilation will be performed using endoscopic equipment with video documentation capability.
Study: NCT02585388

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Vinorelbine metronomic at 50 mg (1 tablet at 20 mg and 1 tablet at 30mg),per oral, 3 times per week. One dose level reduction is authorized at 30 mg per day.when stopping over 3 consecutive weeks due to toxicity, treatment should be permanently discontinued

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine metronomic at 50 mg (1 tablet at 20 mg and 1 tablet at 30mg),per oral, 3 times per week. One dose level reduction is authorized at 30 mg per day.when stopping over 3 consecutive weeks due to toxicity, treatment should be permanently discontinued

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Lestrozole at 2,5 mg every day , per oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Anastrozole at 1 mg every day, per oral
Study: NCT04517045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dachengqi decoction
Description: Raw rhubarb 30g, Glauber's salt 30g, Citrus aurantium 20g, Magnolia officinalis 20g. The decoction was decocted uniformly in the decoction room of Xinhua Hospital, Shanghai Jiaotong University School of Medicine, and decocted 200 mL thickly, fed via nasogastric tube/nasal intestine tube and enema, 1 dose/d, and continued treatment until the end of the trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dachengqi decoction
Description: Raw rhubarb 30g, Glauber's salt 30g, Citrus aurantium 20g, Magnolia officinalis 20g. The decoction was decocted uniformly in the decoction room of Xinhua Hospital, Shanghai Jiaotong University School of Medicine, and decocted 200 mL thickly, fed via nasogastric tube/nasal intestine tube and enema, 1 dose/d, and continued treatment until the end of the trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: probiotic L9
Description: L92 2 tablets/time, tid, oral or nasal feeding

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: probiotic L9
Description: L92 2 tablets/time, tid, oral or nasal feeding

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional treatment
Description: Conventional treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Conventional treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Conventional treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Conventional treatment
Study: NCT01663194

Intervention type: PROCEDURE
Intervention: primary percutaneous coronary intervention, each groups
Description: All primary PCI procedures were performed using the standard femoral approach with a 7-French guiding catheter for each patients. After administration of 5,000 IU of intravenous heparin (70 U/Kg) and a 300 mg loading dose of clopidogrel, direct stenting was performed whenever possible, and in the remaining cases, balloon pre-dilatation was performed. The operator determined the choice of stents (bare metal or drug-eluting stent).

Intervention type: PROCEDURE
Intervention: primary percutaneous coronary intervention, each groups
Description: All primary PCI procedures were performed using the standard femoral approach with a 7-French guiding catheter for each patients. After administration of 5,000 IU of intravenous heparin (70 U/Kg) and a 300 mg loading dose of clopidogrel, direct stenting was performed whenever possible, and in the remaining cases, balloon pre-dilatation was performed. The operator determined the choice of stents (bare metal or drug-eluting stent).

Intervention type: PROCEDURE
Intervention: primary percutaneous coronary intervention, each groups
Description: All primary PCI procedures were performed using the standard femoral approach with a 7-French guiding catheter for each patients. After administration of 5,000 IU of intravenous heparin (70 U/Kg) and a 300 mg loading dose of clopidogrel, direct stenting was performed whenever possible, and in the remaining cases, balloon pre-dilatation was performed. The operator determined the choice of stents (bare metal or drug-eluting stent).
Study: NCT02703818

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Senza
Description: Spinal Cord Stimulation
Study: NCT01794598

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Receiving educational material of depression care
Description: The educational material provides patients about depression management

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Receiving educational material of depression care
Description: The educational material provides patients about depression management
Study: NCT03385369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: Single dose of MEDI0382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: Single dose of MEDI0382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: Single dose of MEDI0382
Study: NCT03241264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-L02-s0201
Description: Specified dose on specified day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-L02-s0201
Description: Specified dose on specified day
Study: NCT00872014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: Two doses of AMG 386 (15 mg/kg) IV QW will be studied

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: Two doses of AMG 386 (10 mg/kg) IV QW will be studied

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 400 mg PO BID orally twice daily in an every 4 week dosing schedule for 15mg/kg cohort \& 10mg/kg cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 400 mg PO BID orally twice daily in an every 4 week dosing schedule for 15mg/kg cohort \& 10mg/kg cohort